ISSN: 2574-7800
Authors: Vivian Li DO,* Kelly Frasier DO MS, Kathleen Click BA, Darianne Zimmer BS, Sriya Kakarla BS, Erica Rankin BA, Evadne Rodriguez BA and Julia Vinagolu-Baur MS, MBA
This analysis of current literature explores specific immunogenomic signatures underlying cutaneous manifestations in systemic sclerosis (SSc), a complex autoimmune disorder characterized by fibrosis, vasculopathy, and immune dysregulation. By employing integrated transcriptomic and epigenomic analyses of skin biopsies obtained from SSc patients presenting varying degrees of cutaneous involvement, researchers aim to discern dysregulated immune pathways, gene expression signatures, and epigenetic modifications correlated with disease progression and severity. Additionally, investigating the therapeutic potential of immune-modulating agents, including JAK inhibitors and immune checkpoint inhibitors, in mitigating skin fibrosis and inflammation in SSc may unlock novel avenues for personalized treatment strategies tailored to the immunogenomic profile of individual patients. Future research should focus on validating identified biomarkers, exploring the mechanistic basis of immunogenomic alterations, and translating these findings into clinical practice to optimize therapeutic outcomes and enhance the management of cutaneous manifestations in SSc.
Keywords: Systemic Sclerosis; Immunogenomics; Epigenetics; Immunotherapy; JAK Inhibitors; Scleroderma
